Celltrion’s Vegzelma: Most-prescribed cancer treatment in Europe

Quick Summary:

According to global pharmaceutical market research firm IQVIA on Wednesday, Vegzelma, also known for its active ingredient bevacizumab, held a 29% market share in Europe at the end of the third quarter of 2024.

Celltrion’s Remsima and Remsima SC, the world’s only subcutaneous injection-type autoimmune disease treatment, posted a combined 66% market share in Europe as of the third quarter of 2024.

DOMINANT PLAYER IN EUROPELast year, Celltrion and its crosstown Korean rival Samsung Bioepis Co.achieved a significant milestone in the European biosimilar market, capturing over 50% market share in the six best-selling blockbuster categories.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: Economy

Markets: South KoreaFranceGermany

Topics: European Share Celltrion Europe Market Cancer Global Celltrion’s Vegzelma Biosimilar Sales

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-02-05 @ 16:08:37 (2 hours ago)

News Timezone: GMT +8:00

News Source URL: kedglobal.com

Language: English

Article Length: 526 words

Reading Time: 3 minutes read

Sentences: 26 lines

Sentence Length: 21 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Korea Economic Daily

News ID: 25905512

View Article Analysis

About Korea Economic Daily

Main Topics: Economy

Official Website: kedglobal.com

Update Frequency: 6 posts per day

Year Established: 1964

Headquarters: South Korea

News Last Updated: 47 minutes ago

Coverage Areas: South Korea

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #91

Publisher Details

Frequently Asked Questions